13807-95-9

Usage

InChI:InChI=1/C11H16O4/c1-14-11-4-2-9(3-5-11)7-15-8-10(13)6-12/h2-5,10,12-13H,6-8H2,1H3

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 100-79-8 (R,S)-2,2-dimethyl-1,3-dioxolane-4-methanol 
• 14289-62-4 1-(allyloxymethyl)-4-methoxybenzene 
• 5660-54-8 [2-(4-methoxy-phenyl)-[1,3]dioxolan-4-yl]-methanol 
• 156147-59-0 4-(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolane 
• 105-13-5 4-Methoxybenzyl alcohol 

Downstream Products

• 302783-31-9 1-(tert-butyl-diphenyl-silanyloxy)-3-(4-methoxy-benzyloxy)-propan-2-ol 
• 121289-23-4 p-methoxybenzyloxyacetaldehyde 
• 1299293-72-3 (4R)-4-benzyl-3-{(2R,3R)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-[(4-methoxybenzyl)oxy]-2-methylbutanoyl}-1,3-oxazolidin-2-one 
• 1299293-73-4 ethyl (2E,4S,5R)-5-{[tert-butyl(dimethyl)silyl]oxy}-6-[(4-methoxybenzyl)oxy]-4-methylhex-2-enoate 
• 1299293-74-5 ethyl (4S,5R)-5-{[tert-butyl(dimethyl)silyl]oxy}-6-[(4-methoxybenzyl)oxy]-4-methylhexanoate 
• 1299293-75-6 (4S,5R)-5-{[tert-butyl(dimethyl)silyl]oxy}-6-[(4-methoxybenzyl)oxy]-4-methylhexanoic acid 
• 1299293-79-0 (1R,2S)-1-[2-(benzyloxy)ethyl]-2-methylpent-4-en-1-yl (4S,5R)-5-{[tert-butyl(dimethyl)-silyl]oxy}-6-[(4-methoxybenzyl)oxy]-4-methylhexanoate 
• 1299293-80-3 (2R,3S)-2-(2-(benzyloxy)ethyl)-6-((3S,4R)-4-tert-butyldimethylsilyloxy-5-(4-methoxybenzyloxy)-3-methylpentyl)-3-methyl-3,4-dihydro-2H-pyran 
• 1299293-81-4 (2R,3S)-5-{(2R,3S)-2-[2-(benzyloxy)ethyl]-3-methyl-3,4-dihydro-2H-pyran-6-yl}-1-[(4-methoxybenzyl)oxy]-3-methylpentan-2-ol 
• 501419-21-2 3R-(tert-butyl-dimethyl-silanyloxy)-4-(4-methoxy-benzyloxy)-2R-methyl-butyraldehyde 
• 501419-20-1 (2S,3R)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-[(4-methoxybenzyl)oxy]-2-methylbutan-1-ol 
• 743472-03-9 (4R)-4-benzyl-3-{(2R,3R)-3-hydroxy-4-[(4-methoxybenzyl)oxy]-2-methylbutanoyl}-1,3-oxazolidin-2-one 
• 1391428-55-9 C₂₅H₃₆O₆ 
• 1421929-85-2 (±)-1-(4-methoxybenzyloxy)but-3-en-2-ol 

Relevant academic research and scientific papers

DRUG CONTAINING TARGETING LIPOSOMES

Described herein are novel, modified targeting peptides which can be incorporated within liposomes. Additionally, described herein are liposomes containing the modified targeting peptides. Liposomes preferably comprise a lipid-based bilayer and at least o

CANNABINOID CONTAINING TARGETING LIPOSOMES

Described herein are liposomes containing modified targeting peptides. Liposomes preferably comprise a lipid-based bilayer and at least one cannabinoid. Also provided herein are methods for making the liposomes, and methods for treatment of diseases of th

Substrate specificity of tuliposide-converting enzyme, a unique non-ester-hydrolyzing carboxylesterase in tulip: Effects of the alcohol moiety of substrate on the enzyme activity

6-Tuliposides A (PosA) and B (PosB) are glucose esters accumulated in tulip (Tulipa gesneriana) as major defensive secondary metabolites. Pos-converting enzymes (TgTCEs), which we discovered previously from tulip, catalyze the conversion reactions of PosA

Enzyme-mediated enantioselective hydrolysis of 1,2-diol monotosylate derivatives bearing an unsaturated substituent

We have succeeded in the easy preparation of optically active 1,2-diol monotosylates bearing an unsaturated substituent via enzymatic hydrolysis. Lipase PS quickly catalyzes the hydrolyses of 2-acetoxybut-3-enyl tosylate, which has a double bond, and 2-acetoxybut-3-ynyl tosylate, which has a triple bond, with excellent enantioselectivity to afford the corresponding optically active compounds. The reaction is also applicable to acetates with a longer chain, which has a double bond at the terminus. To demonstrate the applicability of this method, enantiomerically pure (R)-massoialactone, a natural coconut flavor, has been synthesized from racemic 2-acetoxypent-4-enyl tosylate in several steps. Furthermore, the enzyme can recognize the stereochemistry of olefins, and the (Z)-alkenyl structure is more suitable for the enantioselective hydrolysis than the (E)-isomer.

Next generation macrocyclic and acyclic cationic lipids for gene transfer: Synthesis and in vitro evaluation

Previously we reported the synthesis and in vitro evaluation of four novel, short-chain cationic lipid gene delivery vectors, characterized by acyclic or macrocyclic hydrophobic regions composed of, or derived from, two 7-carbon chains. Herein we describe

I2-catalyzed regioselective oxo- and hydroxy-acyloxylation of alkenes and enol ethers: A facile access to α-acyloxyketones, esters, and diol derivatives

I2-catalyzed oxo-acyloxylation of alkenes and enol ethers with carboxylic acids providing for the high yield synthesis of α-acyloxyketones and esters is described. This unprecedented regioselective oxidative process employs TBHP and Et3/s

Novel macrocyclic and acyclic cationic lipids for gene transfer: Synthesis and in vitro evaluation

The synthesis and in vitro evaluation of four cationic lipid gene delivery vectors, characterized by acyclic or macrocyclic, and saturated or unsaturated hydrophobic regions, is described. The synthesis employed standard protocols, including ring-closing metathesis for macrocyclic lipid construction. All lipoplexes studied, formulated from plasmid DNA and a liposome composed of a synthesized lipid, 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (EPC), and either 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or cholesterol as co-lipid, exhibited plasmid DNA binding and protection from DNase I degradation, and concentration dependent cytotoxicity using Chinese hamster ovary-K1 cells. The transfection efficiency of formulations with cholesterol outperformed those with DOPE, and in many cases the EPC/cholesterol control, and formulations with a macrocyclic lipid (+/- 10:1) outperformed their acyclic counterparts (+/- 3:1).

Synthesis of the spirofungin a core via a domino strategy consisting of olefinic ester ring-closing metathesis and iodospiroacetalization

Olefination of ester 26 which was obtained from acid 20 and alkenol 25 using a reduced titanium ethylidene reagent led to cyclic enol ether 28 which could be cyclized by iodospiroacetalization to the spiroacetal core of the antifungal compound spirofungin

Deracemization of 1,2-diol monotosylate derivatives by a combination of enzymatic hydrolysis with the Mitsunobu inversion using polymer-bound triphenylphosphine

The deracemization of 1,2-diol monotosylate derivatives is achieved by the sequential combination of enzymatic hydrolysis and Mitsunobu inversion using a polymer-bound triphenylphosphine. After the lipase-catalysed hydrolysis of the racemic 2-acetoxyhexyl tosylate, the subsequent Mitsunobu reaction without separation causes an inversion of the resulting (R)-alcohol to give the (S)-enantiomer of the acetate as a single product. In particular, the reaction using the polymer-bound triphenylphosphine also proceeds smoothly, and the product is easily separated by filtration from the polymer-bound reagent and its by-products. This deracemization process is applicable to the preparation of several optically active 1,2-diol monotosylates.

C-(4-methoxybenzyloxymethyl)-N-methylnitrone cycloaddition to highly functionalized pyrrolinone: A regio- and stereoselective approach to new omuralide-salinosporamide a hybrids

An advanced intermediate in the synthesis of new omuralide-salinosporamide A hybrids as potential proteasome 20S inhibitors was prepared in a few steps from methyl pyroglutamate. For this purpose, an O-protected hydroxyethyl chain has been successfully in